Alterity Therapeutics Ltd - ATHE STOCK NEWS

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) will host an investor webcast to discuss new data from the bioMUSE Natural History Study and its implications for the ATH434-202 Phase 2 trial endpoints. The webcast, set for May 29, 2024, in the U.S. and May 30, 2024, in Australia, will feature CEO Dr. David Stamler and Professor Daniel Claassen from Vanderbilt University. Dr. Claassen, a key opinion leader and principal investigator, will provide insights into the study results and their impact. Registration is required to attend the webcast, where investors can ask questions.

Alterity Therapeutics, a biotechnology company, received positive feedback from the Data Monitoring Committee regarding the Phase 2 clinical trial of ATH434 for the treatment of multiple system atrophy (MSA). The trial is progressing as planned, with top-line data expected in January 2025. The study aims to demonstrate the drug's efficacy, safety, and target engagement through various assessments.

Alterity Therapeutics released its Q3 FY24 Quarterly Cash Flow Report, showcasing promising Phase 2 baseline data for ATH434-201 targeting biomarkers for slowing disease progression. The company raised A$5.25M, received a A$3.9M tax incentive refund, and ended the quarter with A$18.3M in cash. Operational updates include positive DMC review for ATH434-201, presentations at AAN, enrollment progress for ATH434-202, and promising results for ATH434 in Parkinson's disease. The bioMUSE study continues to provide valuable data on MSA progression.

Alterity Therapeutics presented new data at the World Orphan Drug Congress USA 2024 demonstrating the potential of ATH434 to treat Friedreich's Ataxia. The study showed that ATH434 acts as an iron chaperone, redistributing iron in the body, which could help reduce labile iron levels and slow disease progression. The unique iron-binding properties of ATH434 set it apart from traditional iron chelators, making it a promising treatment for neurodegenerative diseases.

Alterity Therapeutics presented data at the American Academy of Neurology 2024 Annual Meeting showcasing the positive effects of ATH434 in Parkinson's Disease and Multiple System Atrophy. The company's work in Parkinson's disease and MSA, including baseline data from the ATH434-201 Phase 2 trial, was highlighted. The data demonstrated improvements in motor skills and general functioning in a primate model of Parkinson's disease, validating the approach used in ongoing clinical trials. The baseline characteristics from the Phase 2 trial showed increased iron levels in areas of pathology and elevated plasma Neurofilament Light Chain levels correlating with disease severity. The results suggest ATH434's potential as a disease-modifying therapy for neurodegenerative diseases.

Alterity Therapeutics (NASDAQ: ATHE) to present new data on ATH434 at World Orphan Drug Congress and American Academy of Neurology meetings. The data focuses on unique iron-targeting drug for neurodegenerative diseases.

Alterity Therapeutics receives A$3.9 million cash refund for R&D activities, to advance Phase 2 clinical trials in MSA.

Alterity Therapeutics to Present Positive Efficacy Data for ATH434 in Parkinson's Disease Model at AAN 2024 Meeting

Alterity Therapeutics announces that the ATH434-201 Phase 2 clinical trial for treating multiple system atrophy (MSA) is on track to complete in November 2024, with top-line data expected in January 2025. An independent Data Monitoring Committee has recommended the study to continue as planned, with no concerns expressed during the review of unblinded clinical data.